secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001193125-25-050880
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics appoints Christopher Cain to board; Peter Harwin resigns effective March 10
--------------------------------------------------------------------------------

- Christopher Cain (Director of Research, Fairmount Funds Management) named Class I director and chair of Nominating and Corporate Governance Committee.
- Peter Harwin resigned from the board effective March 10, 2025, with no disagreement with the company.
- Cain also joins the Audit Committee and Science & Technology Committee; standard director compensation applies.
- Cain previously served at Samsara BioCapital, Apple Tree Partners, RA Capital Management, and BioCentury.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/d937334d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-050880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer